A drug discovery engine
for genetic diseases
A drug
discovery
engine for
genetic
diseases
for genetic diseases
discovery
engine for
genetic
diseases
Treating individuals with rare diseases
to uncover solutions for millions
to uncover solutions for millions
From personalized medicine for individuals to precision medicine for populations
QR genetics develop a powerful AI-supported drug discovery engine
that identifies potential therapies for common genetic diseases,
by uncovering new treatments for individual patients with similar rare disease mutations
From personalized medicine for individuals to precision medicine for populations QR genetics develop a powerful AI-supported drug discovery engine
that identifies potential therapies for
common genetic diseases,
by uncovering new treatments for individual patients with similar rare disease mutations
Our Unique Discovery Process
01
Patient
data
data
Disease
data
data
Proprietary
database
database
Proprietary
Algorithms
Algorithms
Disease
Modeling
Modeling
Protein
Modeling
Modeling
Target
Identification
Identification
Drug
Discovery
Discovery
02
Rapid clinical validation through preclinical tests, & in-human trials
03
Proprietary
Algorithms
Algorithms
AI-driven Data processing to locate prevalent diseases with spatially similar functional disorders
04
Pre-clinical and Clinical trials in partnership with pharma or academia
Our discovery edge
De-risking the clinical stages of drug development through in-human validation
Discovery time reduction from 3 years to 3 months
Parallel exploration of multiple diseases and drug candidates
Autism Case Study
Pre-treatment
7 years old
Was diagnosed with Autism spectrum disorder-level 3, caused by a point mutation that impacted his growth and development.
POST-treatment
8 years old
After 1 year of treatment with a repurposed drug.
Knows how to read. Can communicate with his surroundings, with friends and with family.
Knows how to read. Can communicate with his surroundings, with friends and with family.
Drug Indication
Expansion
Therapy was found beneficial for
> 100,000
autism patients with a specific mutated protein
Pipeline
Drug
name
name
Indication
type
type
Indication
name
name
Pre-clinical trial
Results
Clinical partner research
Clinical trial
QR-100
Rare
Common
Neurodevelopmental disorder (NDPLH)
Autism Spectrum Disorder (ASD)
QR-295
Rare
Common
Central core disease of muscle (CCD)
Myopathy
QR-172
Rare
Common
Common
Common
Common
Common
Common
Common
Smooth Muscle Disease
Cardiomyopathy
Abdominal and aortic Aneurysm
Visceral myopathy
Deafness
Dystonia
Nemaline Myopathy
Basal cell carcinoma
Management team
Dr. Shane Wald Altman. Ph.D.
Co-Founder & CEO
Prof. Miguel Weil, Ph.D.
Co-Founder & Scientific advisor
Dan Lavi
Co-Founder, Entrepreneur
& Business Management
& Business Management
Dr. Noa Bielopolski, Ph.D.
Director of Science
Ido Gonen
Board Member and
Business development
consultant
Business development
consultant
Dr. Dan Goldstaub
Board member
and Pharma consultant
and Pharma consultant
Collaborators
Prof. Arnold Levine
Board Member and
Cancer research specialist
Cancer research specialist
